GlaxoSmithKline 'Pay For Delay' Suit Heads To EU Court
A United Kingdom tribunal punted on GlaxoSmithKline PLC's appeal over £37.6 million ($54 million) in antitrust fines from alleged "pay-for-delay" deals to postpone generic versions of blockbuster antidepressant Seroxat, sending the...To view the full article, register now.
Already a subscriber? Click here to view full article